ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,841 to 3,860 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Arm 1 vs Arm 2: Primary Major Macrovascular Events264 of 899

235 of 892

3.0 points

-1.1 to 7.2

1,791NCT00032487

Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)

Arm 1 vs Arm 2: serious adverse events144 of 899

197 of 892

-6.1 points

-9.7 to -2.4

1,791NCT00032487

Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)

Cardiac Resynchronization Therapy + Defibrillator vs Implantable Cardioverter Defibrillator Alone: serious adverse events164 of 1,079

55 of 712

7.5 points

4.5 to 10.3

1,791NCT00180271

MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy

465 VADT Participants - Standard vs 465 VADT Participants -Intensive: The Long Term Effects of Intensive Glycemic Control in Type 2 Diabetes on the Secondary Outcome Cardiovascular Mortality.125 of 899

118 of 892

0.7 points

-2.5 to 3.9

1,791NCT00756613

The VA Diabetes Trial Follow-up Study (VADT-FS)

465 VADT Participants - Standard vs 465 VADT Participants -Intensive: The Long Term Effects of Intensive Glycemic Control in Type 2 Diabetes on the Secondary Outcome Total Mortality.366 of 899

376 of 892

-1.4 points

-6.0 to 3.1

1,791NCT00756613

The VA Diabetes Trial Follow-up Study (VADT-FS)

(SIIV+20vPnC)/Saline: Coadministration vs (SIIV+Saline)/20vPnC: Separate Administration: deaths from any cause2 of 895

3 of 896

-0.1 points

-0.8 to 0.5

1,791NCT04526574

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

(SIIV+20vPnC)/Saline: Coadministration vs (SIIV+Saline)/20vPnC: Separate Administration: serious adverse events33 of 895

33 of 896

0.0 points

-1.8 to 1.8

1,791NCT04526574

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Transdisciplinary Approach vs Multidisciplinary Approach: Dispensing of Psychotropic Medications107 of 487

227 of 1,303

4.5 points

0.5 to 8.9

1,790NCT03442322

Optimizing Care for Patients With Dementia

SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Married and Co-habiting With Husband [by Trial End Line]43 of 912

46 of 876

-0.5 points

-2.6 to 1.5

1,788NCT01996241

Evaluation of an Intervention for Adolescent Girls in Karnataka

SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Passing 10th Standard [Pass 10th Standard Exam]518 of 912

530 of 876

-3.7 points

-8.2 to 0.9

1,788NCT01996241

Evaluation of an Intervention for Adolescent Girls in Karnataka

SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Married [by Trial End Line]92 of 912

84 of 876

0.5 points

-2.3 to 3.3

1,788NCT01996241

Evaluation of an Intervention for Adolescent Girls in Karnataka

SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Completing Secondary School [Sit 10th Standard Exam]680 of 912

658 of 876

-0.6 points

-4.6 to 3.5

1,788NCT01996241

Evaluation of an Intervention for Adolescent Girls in Karnataka

SC/ST Girls in Intervention Village Cluster vs SC/ST Girls in Control Village Cluster: Number of Participants Having Sexual Debut [by Trial End Line]64 of 912

53 of 876

1.0 points

-1.3 to 3.3

1,788NCT01996241

Evaluation of an Intervention for Adolescent Girls in Karnataka

CACHET - Ocular vs CACHET - Systemic: deaths from any cause0 of 1,123

3 of 657

-0.5 points

-1.3 to -0.0

1,780NCT01497067

Long Term Safety Protocol for the AcrySof CACHET Phakic Lens

CACHET - Ocular vs CACHET - Systemic: serious adverse events276 of 1,123

24 of 657

20.9 points

17.9 to 23.8

1,780NCT01497067

Long Term Safety Protocol for the AcrySof CACHET Phakic Lens

Cenicriviroc 150 mg vs Placebo: deaths from any cause6 of 1,185

2 of 593

0.2 points

-0.8 to 0.8

1,778NCT03028740

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Narrow Spectrum Antibiotic vs Non-narrow Spectrum Antibiotic: Symptoms Present on Day 3427 of 1,128

267 of 647

-3.4 points

-8.2 to 1.3

1,775NCT02297815

Comparative Effectiveness of Antibiotics for Respiratory Infections

All TNFI Initiators Monotherapy vs Tofacitinib Initiators Combination: Number of Participants With mACR20 at 6 Months for Tofacitinib Combination With MTX vs TNFi Monotherapy394 of 1,683

19 of 90

2.3 points

-7.4 to 9.8

1,773NCT05576051

To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

Cenicriviroc 150 mg vs Placebo: serious adverse events159 of 1,180

70 of 589

1.6 points

-1.8 to 4.7

1,769NCT03028740

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Inpatient vs Outpatient: Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient99 of 127

1,410 of 1,638

-8.1 points

-16.3 to -1.6

1,765NCT00605865

Drug Use Investigation of Jzoloft.

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=193"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=193

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00032487-6ac6ebfb",
        "title": "Arm 1 vs Arm 2: Primary Major Macrovascular Events",
        "summary": "264 of 899 against 235 of 892; risk difference 3.0 points, 95% interval -1.1 to 7.2; NCT00032487, Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)",
        "record": "/library/comparisons/NCT00032487-6ac6ebfb",
        "nct_id": "NCT00032487",
        "kind": "outcome",
        "participants": 1791,
        "risk_difference": {
          "value": 0.030206707003795963,
          "lower": -0.011321739065687578,
          "upper": 0.07158151726302422
        },
        "group_1": "264 of 899",
        "group_2": "235 of 892",
        "difference": "3.0 points",
        "interval": "-1.1 to 7.2",
        "trial_title": "Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)"
      },
      {
        "id": "NCT00032487-sae",
        "title": "Arm 1 vs Arm 2: serious adverse events",
        "summary": "144 of 899 against 197 of 892; risk difference -6.1 points, 95% interval -9.7 to -2.4; NCT00032487, Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)",
        "record": "/library/comparisons/NCT00032487-sae",
        "nct_id": "NCT00032487",
        "kind": "serious-adverse-events",
        "participants": 1791,
        "risk_difference": {
          "value": -0.06067404240885488,
          "lower": -0.09691048393792638,
          "upper": -0.024321455113189984
        },
        "group_1": "144 of 899",
        "group_2": "197 of 892",
        "difference": "-6.1 points",
        "interval": "-9.7 to -2.4",
        "trial_title": "Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=194",
  "request_id": "YguA3yz3QqJB_KyP"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?